|
Prostate carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
FABP5 was overexpressed in PCa compared to BPH in the cohorts analyzed by qRT-PCR (radical prostatectomy p = 0.003, p = 0.010; pTUR-P p = 0.002).
|
30701334 |
2020 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
FABP5 in urinary EVs could be a potential biomarker of high GS PCa.
|
28211531 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The expression and subcellular distribution of two RA-binding proteins, FABP5 and CRABP2, has already been shown to play critical roles in breast cancer cell response to RA.
|
26142905 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
FABP5 knockdown in breast cancer cell lines demonstrates a correlation between FABP5 levels and growth response to RA.
|
21356353 |
2011 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Further, immunohistochemistry was performed to detect differential expression of ATGL and FABP5 in breast cancer tissue sections.
|
29914512 |
2018 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In this study, the inhibitory effects of ATPR on the proliferation, invasion, and migration of breast cancer (BC) cells, and the relationship between ATPR and the expression of the intracellular lipid-binding proteins CRABP2 and FABP5 were investigated.
|
29731607 |
2018 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our studies show that FABP5 has a role in both host and tumor cell during breast cancer progression.
|
25779666 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Fatty acid-binding protein 4 was positively associated with age, body mass index (BMI), FABP5, very-low-density lipoprotein cholesterol (VLDLc), non-high-density lipoprote in cholesterol (non-HDLc), Apolipoprotein B 100 (ApoB100), triglycerides, glycerol, glucose, and hsCRP (<i>p</i> < .05), and was negatively associated with HDLc (<i>p</i> < .005) in breast cancer patients.
|
28701570 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
FABP5 is associated with increased subclinical atherosclerosis.
|
27055964 |
2016 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, in contrast to FABP4, circulating FABP5 is associated with decreased CEC and carotid atherosclerosis, suggesting that FABP5 level is a regulatory factor of CEC and a potential biomarker for residual risk of atherosclerosis.
|
28303004 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models.
|
26260145 |
2015 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models.
|
26260145 |
2015 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, in contrast to FABP4, circulating FABP5 is associated with decreased CEC and carotid atherosclerosis, suggesting that FABP5 level is a regulatory factor of CEC and a potential biomarker for residual risk of atherosclerosis.
|
28303004 |
2017 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
FABP5 is associated with increased subclinical atherosclerosis.
|
27055964 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High FABP5 expression was also significantly correlated with tumor and metastasis classifications and predicted poor survival in patients with ccRCC.
|
30968158 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this study, through multiple analysis and verification of multiple databases, such as ONCOMINE, The Human Protein Atlas, UALCAN, Gene Expression Profiling Interactive Analysis, and cBioPortal, we found that the expression of FABP1 was significantly downregulated and the expression of FABP5/6/7 was significantly upregulated in ccRCC compared with renal tissues, and the patients with high messenger RNA (mRNA) levels of the FABP5/6/7 or low mRNA levels of FABP1 were predicted to have a lower overall survival or disease-free survival.
|
31602654 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In summary, our data suggest that FABP5 may be a potential therapeutic target in ccRCC.
|
31491402 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies revealed that FABP5 knockdown in TNBC cells results in decreased EGFR expression and FABP5 is important for EGF-induced metastatic signaling.
|
25779666 |
2015 |
|
Triple Negative Breast Neoplasms
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy.
|
21356353 |
2011 |
|
Triple Negative Breast Neoplasms
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, up-regulation of FABP5 is strongly associated with poor survival in triple-negative breast cancer.
|
26614767 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies revealed that FABP5 knockdown in TNBC cells results in decreased EGFR expression and FABP5 is important for EGF-induced metastatic signaling.
|
25779666 |
2015 |
|
Triple-Negative Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, up-regulation of FABP5 is strongly associated with poor survival in triple-negative breast cancer.
|
26614767 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy.
|
21356353 |
2011 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
DHA supplementation has been shown to be beneficial in various mouse models of AD, and therefore, the aim of this study was to determine whether DHA has the potential to up-regulate the BBB expression of FABP5, thereby enhancing its own uptake into the brain.
|
29582413 |
2018 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
This study reports a 42.1 ± 12.6% decrease in the BBB transport of <sup>14</sup> C-DHA in 8-month-old AD transgenic mice (APPswe,PSEN1∆E9) relative to wild-type mice, associated with a 34.5 ± 6.7% reduction in FABP5 expression in isolated brain capillaries of AD mice.
|
29105065 |
2018 |